Review



tlr7 8 agonist r848  (InvivoGen)


Bioz Verified Symbol InvivoGen is a verified supplier
Bioz Manufacturer Symbol InvivoGen manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99

    Structured Review

    InvivoGen tlr7 8 agonist r848
    Tlr7 8 Agonist R848, supplied by InvivoGen, used in various techniques. Bioz Stars score: 99/100, based on 2393 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tlr7+8+agonist+r848/R848/pm42668088-237-31-36
    Average 99 stars, based on 2393 article reviews
    tlr7 8 agonist r848 - by Bioz Stars, 2026-10
    99/100 stars

    Images

    Related Articles

    Incubation:

    Article Title: A novel Toll-like receptor 7/8-specific antagonist E6742 ameliorates clinically relevant disease parameters in murine models of lupus.
    Article Snippet: DOTAP was purchased as a 1-mg/mL stock (Roche 11-202-375 001, Sigma Aldrich). .. Cells were further incubated at 37 ◦C, 5% CO2 for 20 or 44 h. In the selectivity assay, PBMCs were treated for 60 minutes with E6742 (final concentration 0.003–10 μM) dilutions before their stimulation with TLR agonists for 24 h. The following agonists were used: TLR2 agonist, Pam3CSK4 (InvivoGen) at 10 ng/mL; TLR3 agonist, poly (I:C) (InvivoGen) at 75 μg/mL; TLR4 agonist, LPS (List Biological Lab) at 10 ng/mL; TLR5 agonist, FLA-BS (InvivoGen) at 0.4 μg/mL; TLR7/8 agonist R848 (InvivoGen) at 3 μM; and TLR9 agonist, ODN2006–DOTAP (InvivoGen/Roche) at 0.25 μM (ODN2006) and 20 μg/mL (DOTAP). .. IL-6 and IFN-α levels in supernatants were measured by using a standard ELISA procedure (BD Biosciences and R&D Systems, respectively).

    Article Title: Hepatitis B surface antigen directly alters Dendritic cell-mediated Natural Killer cell responses.
    Article Snippet: .. After a 4-hour incubation, specific TLR ligands (TLR-L) were used depending on the DC subtype: PanDC were stimulated or not with the TLR3 agonist polyinosine-polycytidylic acid (Poly(I:C)) at 30μg/mL (Invivogen), the TLR7/8 agonist R848 at 1μg/mL (Invivogen), or the TLR9 agonist class-A CpG oligonucleotide (CpGA) at 1μM (Invivogen); cDC1 were stimulated with Poly(I:C) or left unstimulated; cDC2 were stimulated with R848 or left unstimulated; pDC were stimulated with R848, CpGA, or left unstimulated. .. Dendritic Cell Culture and TLR ligand stimulation The culture medium was prepared using RPMI-1640/GlutaMAX (Invitrogen), supplemented with 1% MEM (100X) non-essential amino acids (Invitrogen), 20μg/mL Gentamycin (Invitrogen), 1 mM Sodium Pyruvate (Sigma-Aldrich), and 10% human serum.

    Concentration Assay:

    Article Title: A novel Toll-like receptor 7/8-specific antagonist E6742 ameliorates clinically relevant disease parameters in murine models of lupus.
    Article Snippet: DOTAP was purchased as a 1-mg/mL stock (Roche 11-202-375 001, Sigma Aldrich). .. Cells were further incubated at 37 ◦C, 5% CO2 for 20 or 44 h. In the selectivity assay, PBMCs were treated for 60 minutes with E6742 (final concentration 0.003–10 μM) dilutions before their stimulation with TLR agonists for 24 h. The following agonists were used: TLR2 agonist, Pam3CSK4 (InvivoGen) at 10 ng/mL; TLR3 agonist, poly (I:C) (InvivoGen) at 75 μg/mL; TLR4 agonist, LPS (List Biological Lab) at 10 ng/mL; TLR5 agonist, FLA-BS (InvivoGen) at 0.4 μg/mL; TLR7/8 agonist R848 (InvivoGen) at 3 μM; and TLR9 agonist, ODN2006–DOTAP (InvivoGen/Roche) at 0.25 μM (ODN2006) and 20 μg/mL (DOTAP). .. IL-6 and IFN-α levels in supernatants were measured by using a standard ELISA procedure (BD Biosciences and R&D Systems, respectively).

    Adjuvant:

    Article Title: Calboxyvinyl polymer adjuvant enhances respiratory iga responses through mucosal and systemic administration.
    Article Snippet: SARS-CoV-2 (Wuhan strain) spike protein S1 with Fc-tag antigen and SARS-CoV-2 (Wuhan strain) spike trimer proteinwere obtained fromACROBio systems (Newark, DE, USA). .. The following commercially available adjuvants were used: aluminum hydroxide gel (Alhydrogel, alum), squalene-based oil-inwater adjuvant AddaVax,murine STING ligandDMXaa, Toll-like receptor 1/2 (TLR1/2) agonist Pam3CSK4, TLR3 agonist poly I:C, CpG ODN2006, and TLR7/8 agonist R848 obtained from InvivoGen (SanDiego, CA, USA). ..

    Immunofluorescence:

    Article Title: Clinical features associated with the presence of anti-Ro52 and anti-Ro60 antibodies in Jo-1 antibody-positive anti-synthetase syndrome
    Article Snippet: Recombinant Ro52 (ProSpec-Tany TechnoGene Ltd, Ness‐Ziona, Israel) and Ro60 (US Biological, Salem, Massachusetts) were obtained from commercial sources, as indicated. .. In our study, experimental mice received IM injections of IFA emulsions [administered to both hamstrings in a total volume of 150 μl (75 μl per side)]] containing the TLR7/8 agonist R848 (Invivogen, San Diego, California; 0.1 μg/ml) and either MA/MBP (1.2 mg/ml) or phosphate-buffered saline (PBS). ..

    Saline:

    Article Title: Clinical features associated with the presence of anti-Ro52 and anti-Ro60 antibodies in Jo-1 antibody-positive anti-synthetase syndrome
    Article Snippet: Recombinant Ro52 (ProSpec-Tany TechnoGene Ltd, Ness‐Ziona, Israel) and Ro60 (US Biological, Salem, Massachusetts) were obtained from commercial sources, as indicated. .. In our study, experimental mice received IM injections of IFA emulsions [administered to both hamstrings in a total volume of 150 μl (75 μl per side)]] containing the TLR7/8 agonist R848 (Invivogen, San Diego, California; 0.1 μg/ml) and either MA/MBP (1.2 mg/ml) or phosphate-buffered saline (PBS). ..

    other:

    Article Title: Calboxyvinyl polymer adjuvant enhances respiratory iga responses through mucosal and systemic administration
    Article Snippet: SARS-CoV-2 (Wuhan strain) spike protein S1 with Fc-tag antigen and SARS-CoV-2 (Wuhan strain) spike trimer protein were obtained from ACROBio systems (Newark, DE, USA).



    Similar Products

    99
    InvivoGen tlr7 8 agonist r848
    Tlr7 8 Agonist R848, supplied by InvivoGen, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tlr7+8+agonist+r848/R848/pm42668088-237-31-36
    Average 99 stars, based on 1 article reviews
    tlr7 8 agonist r848 - by Bioz Stars, 2026-10
    99/100 stars
      Buy from Supplier

    99
    InvivoGen tlr7 8 agonist
    Tlr7 8 Agonist, supplied by InvivoGen, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tlr7+8+agonist+r848/R848/10__1038_slash_s41598___026___66036___9-132-43-47
    Average 99 stars, based on 1 article reviews
    tlr7 8 agonist - by Bioz Stars, 2026-10
    99/100 stars
      Buy from Supplier

    99
    InvivoGen tlr7 8 agonist resiquimod
    Tlr7 8 Agonist Resiquimod, supplied by InvivoGen, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tlr7+8+agonist+r848/R848/pm41981680-99-9-15
    Average 99 stars, based on 1 article reviews
    tlr7 8 agonist resiquimod - by Bioz Stars, 2026-10
    99/100 stars
      Buy from Supplier

    96
    MedChemExpress tlr7 8 agonist r848 compound
    Frequency and functions comparisons of DC subsets in females and males. (A) Representative flow cytometry gating strategy for the identification of human DC subsets. Home-made lineage markers included CD3, CD19, CD56. AXL + DC: lineage - HLA-DR + AXL + ; pDCs: lineage - HLA-DR + AXL - CD11c - CD123 + ; CD141 + DC: lineage - HLA-DR + AXL - CD123 - CD11c + CD1c - CD141 + ; CD1c + DC: lineage - HLA-DR + AXL - CD123 - CD11c + CD141 - CD1c + . (B) Comparative analysis of the relative frequencies of DC subsets (AXL + DC, pDCs, CD1c + DC, CD141 + DC, and CD1c - CD141 - DC) in PBMCs between males (n = 46) and females (n = 45). (C) Correlation between donor age and the frequency of pDCs (left) and AXL + DCs (right). Each dot represents an individual donor. (D) The UpSet plot illustrating the integrated comparative analysis of differentially expressed genes (DEGs) in DC subsets between females and males. (E) Functional pathway enrichment analysis of DEGs in CD141 + DC, CD1c + DC, and pDCs, as determined by Ingenuity Pathway Analysis (IPA). The color scale represents the activation z-score, with red indicating pathway activation and blue indicating inhibition. Gray indicates that an activation state could not be determined. (F) Predicted upstream regulators of the DEGs in each DC subset from females compared to males. The color scale represents the activation z-score, with red indicating predicted activation and blue indicating predicted inhibition of the regulator in females. (G) Mean Fluorescence Intensity (MFI) of HLA-DR on CD141 + DC, CD1c + DC, and pDCs, comparing male and female donors. (H) Relative expression of IFN-β in <t>R848-stimulated</t> pDCs from females (n=10) and males (n =10), measured by qPCR, and IFN-beta secretion into the supernatant, quantified by ELISA. Data was shown as mean ± SD. Statistical significance for comparisons between two groups was determined using the Mann-Whitney test. Correlations in (C) were assessed by Spearman’s rank correlation. Significance levels are denoted as follows: ns,not significant; * p < 0.05, ** p < 0.01.
    Tlr7 8 Agonist R848 Compound, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tlr7+8+agonist+r848/Resiquimod/pmc13070752-219-29-34
    Average 96 stars, based on 1 article reviews
    tlr7 8 agonist r848 compound - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    95
    MedChemExpress tlr7 8 agonist resiquimod r848
    Frequency and functions comparisons of DC subsets in females and males. (A) Representative flow cytometry gating strategy for the identification of human DC subsets. Home-made lineage markers included CD3, CD19, CD56. AXL + DC: lineage - HLA-DR + AXL + ; pDCs: lineage - HLA-DR + AXL - CD11c - CD123 + ; CD141 + DC: lineage - HLA-DR + AXL - CD123 - CD11c + CD1c - CD141 + ; CD1c + DC: lineage - HLA-DR + AXL - CD123 - CD11c + CD141 - CD1c + . (B) Comparative analysis of the relative frequencies of DC subsets (AXL + DC, pDCs, CD1c + DC, CD141 + DC, and CD1c - CD141 - DC) in PBMCs between males (n = 46) and females (n = 45). (C) Correlation between donor age and the frequency of pDCs (left) and AXL + DCs (right). Each dot represents an individual donor. (D) The UpSet plot illustrating the integrated comparative analysis of differentially expressed genes (DEGs) in DC subsets between females and males. (E) Functional pathway enrichment analysis of DEGs in CD141 + DC, CD1c + DC, and pDCs, as determined by Ingenuity Pathway Analysis (IPA). The color scale represents the activation z-score, with red indicating pathway activation and blue indicating inhibition. Gray indicates that an activation state could not be determined. (F) Predicted upstream regulators of the DEGs in each DC subset from females compared to males. The color scale represents the activation z-score, with red indicating predicted activation and blue indicating predicted inhibition of the regulator in females. (G) Mean Fluorescence Intensity (MFI) of HLA-DR on CD141 + DC, CD1c + DC, and pDCs, comparing male and female donors. (H) Relative expression of IFN-β in <t>R848-stimulated</t> pDCs from females (n=10) and males (n =10), measured by qPCR, and IFN-beta secretion into the supernatant, quantified by ELISA. Data was shown as mean ± SD. Statistical significance for comparisons between two groups was determined using the Mann-Whitney test. Correlations in (C) were assessed by Spearman’s rank correlation. Significance levels are denoted as follows: ns,not significant; * p < 0.05, ** p < 0.01.
    Tlr7 8 Agonist Resiquimod R848, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tlr7+8+agonist+r848/Resiquimod/pm41791134-97-13-17
    Average 95 stars, based on 1 article reviews
    tlr7 8 agonist resiquimod r848 - by Bioz Stars, 2026-10
    95/100 stars
      Buy from Supplier

    86
    Mabtech Inc tlr7 8 agonist r848 resiquimod
    Frequency and functions comparisons of DC subsets in females and males. (A) Representative flow cytometry gating strategy for the identification of human DC subsets. Home-made lineage markers included CD3, CD19, CD56. AXL + DC: lineage - HLA-DR + AXL + ; pDCs: lineage - HLA-DR + AXL - CD11c - CD123 + ; CD141 + DC: lineage - HLA-DR + AXL - CD123 - CD11c + CD1c - CD141 + ; CD1c + DC: lineage - HLA-DR + AXL - CD123 - CD11c + CD141 - CD1c + . (B) Comparative analysis of the relative frequencies of DC subsets (AXL + DC, pDCs, CD1c + DC, CD141 + DC, and CD1c - CD141 - DC) in PBMCs between males (n = 46) and females (n = 45). (C) Correlation between donor age and the frequency of pDCs (left) and AXL + DCs (right). Each dot represents an individual donor. (D) The UpSet plot illustrating the integrated comparative analysis of differentially expressed genes (DEGs) in DC subsets between females and males. (E) Functional pathway enrichment analysis of DEGs in CD141 + DC, CD1c + DC, and pDCs, as determined by Ingenuity Pathway Analysis (IPA). The color scale represents the activation z-score, with red indicating pathway activation and blue indicating inhibition. Gray indicates that an activation state could not be determined. (F) Predicted upstream regulators of the DEGs in each DC subset from females compared to males. The color scale represents the activation z-score, with red indicating predicted activation and blue indicating predicted inhibition of the regulator in females. (G) Mean Fluorescence Intensity (MFI) of HLA-DR on CD141 + DC, CD1c + DC, and pDCs, comparing male and female donors. (H) Relative expression of IFN-β in <t>R848-stimulated</t> pDCs from females (n=10) and males (n =10), measured by qPCR, and IFN-beta secretion into the supernatant, quantified by ELISA. Data was shown as mean ± SD. Statistical significance for comparisons between two groups was determined using the Mann-Whitney test. Correlations in (C) were assessed by Spearman’s rank correlation. Significance levels are denoted as follows: ns,not significant; * p < 0.05, ** p < 0.01.
    Tlr7 8 Agonist R848 Resiquimod, supplied by Mabtech Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tlr7+8+agonist+r848/r848/pm41315325-173-1-12
    Average 86 stars, based on 1 article reviews
    tlr7 8 agonist r848 resiquimod - by Bioz Stars, 2026-10
    86/100 stars
      Buy from Supplier

    Image Search Results


    Frequency and functions comparisons of DC subsets in females and males. (A) Representative flow cytometry gating strategy for the identification of human DC subsets. Home-made lineage markers included CD3, CD19, CD56. AXL + DC: lineage - HLA-DR + AXL + ; pDCs: lineage - HLA-DR + AXL - CD11c - CD123 + ; CD141 + DC: lineage - HLA-DR + AXL - CD123 - CD11c + CD1c - CD141 + ; CD1c + DC: lineage - HLA-DR + AXL - CD123 - CD11c + CD141 - CD1c + . (B) Comparative analysis of the relative frequencies of DC subsets (AXL + DC, pDCs, CD1c + DC, CD141 + DC, and CD1c - CD141 - DC) in PBMCs between males (n = 46) and females (n = 45). (C) Correlation between donor age and the frequency of pDCs (left) and AXL + DCs (right). Each dot represents an individual donor. (D) The UpSet plot illustrating the integrated comparative analysis of differentially expressed genes (DEGs) in DC subsets between females and males. (E) Functional pathway enrichment analysis of DEGs in CD141 + DC, CD1c + DC, and pDCs, as determined by Ingenuity Pathway Analysis (IPA). The color scale represents the activation z-score, with red indicating pathway activation and blue indicating inhibition. Gray indicates that an activation state could not be determined. (F) Predicted upstream regulators of the DEGs in each DC subset from females compared to males. The color scale represents the activation z-score, with red indicating predicted activation and blue indicating predicted inhibition of the regulator in females. (G) Mean Fluorescence Intensity (MFI) of HLA-DR on CD141 + DC, CD1c + DC, and pDCs, comparing male and female donors. (H) Relative expression of IFN-β in R848-stimulated pDCs from females (n=10) and males (n =10), measured by qPCR, and IFN-beta secretion into the supernatant, quantified by ELISA. Data was shown as mean ± SD. Statistical significance for comparisons between two groups was determined using the Mann-Whitney test. Correlations in (C) were assessed by Spearman’s rank correlation. Significance levels are denoted as follows: ns,not significant; * p < 0.05, ** p < 0.01.

    Journal: Frontiers in Immunology

    Article Title: Integrated analysis of sex differences in human dendritic cell, monocyte, and natural killer cell subsets

    doi: 10.3389/fimmu.2026.1750775

    Figure Lengend Snippet: Frequency and functions comparisons of DC subsets in females and males. (A) Representative flow cytometry gating strategy for the identification of human DC subsets. Home-made lineage markers included CD3, CD19, CD56. AXL + DC: lineage - HLA-DR + AXL + ; pDCs: lineage - HLA-DR + AXL - CD11c - CD123 + ; CD141 + DC: lineage - HLA-DR + AXL - CD123 - CD11c + CD1c - CD141 + ; CD1c + DC: lineage - HLA-DR + AXL - CD123 - CD11c + CD141 - CD1c + . (B) Comparative analysis of the relative frequencies of DC subsets (AXL + DC, pDCs, CD1c + DC, CD141 + DC, and CD1c - CD141 - DC) in PBMCs between males (n = 46) and females (n = 45). (C) Correlation between donor age and the frequency of pDCs (left) and AXL + DCs (right). Each dot represents an individual donor. (D) The UpSet plot illustrating the integrated comparative analysis of differentially expressed genes (DEGs) in DC subsets between females and males. (E) Functional pathway enrichment analysis of DEGs in CD141 + DC, CD1c + DC, and pDCs, as determined by Ingenuity Pathway Analysis (IPA). The color scale represents the activation z-score, with red indicating pathway activation and blue indicating inhibition. Gray indicates that an activation state could not be determined. (F) Predicted upstream regulators of the DEGs in each DC subset from females compared to males. The color scale represents the activation z-score, with red indicating predicted activation and blue indicating predicted inhibition of the regulator in females. (G) Mean Fluorescence Intensity (MFI) of HLA-DR on CD141 + DC, CD1c + DC, and pDCs, comparing male and female donors. (H) Relative expression of IFN-β in R848-stimulated pDCs from females (n=10) and males (n =10), measured by qPCR, and IFN-beta secretion into the supernatant, quantified by ELISA. Data was shown as mean ± SD. Statistical significance for comparisons between two groups was determined using the Mann-Whitney test. Correlations in (C) were assessed by Spearman’s rank correlation. Significance levels are denoted as follows: ns,not significant; * p < 0.05, ** p < 0.01.

    Article Snippet: The total pDCs were isolated from PBMCs using EasySep human pDCs isolation kit (Stemcell, Cat. no17977) and 900 pDCs was plated in 96U plate, cells were stimulated with 10ng/ml TLR7/8 agonist R848 compound (TLRL-R848, MCE) for 24hours.

    Techniques: Flow Cytometry, Functional Assay, Activation Assay, Inhibition, Fluorescence, Expressing, Enzyme-linked Immunosorbent Assay, MANN-WHITNEY